Altman, 2004
|
High
|
Yes
|
Bio-HA
|
NR
|
Single 60 mg/3 ml injection of IA-HA or saline
|
Altman, 2009
|
High
|
No
|
Bio-HA
|
Suprapatellar or infrapatellar approach
|
3 weekly injections of IA-HA (20 mg/2 ml) or saline
|
Arden, 2014
|
High
|
Yes
|
Bio-HA
|
Lateral midpatellar, lateral upper-patellar or medial
|
Single 3 ml injectionof IA-HA (60 mg/3 ml) or saline
|
Brandt, 2001
|
Moderate
|
No
|
Bio-HA
|
NR
|
3 weekly injections of IA-HA (2 ml; 15 mg/ml) or saline (2 ml)
|
Chevalier, 2010
|
High
|
Yes
|
ADHA
|
NR
|
Single 6 ml injectionof IA-HA or saline
|
Creamer, 1994
|
Low
|
No
|
ADHA
|
NR
|
Single injection of HA (20 mg/2 ml) into one knee and saline (2 ml) into the other
|
Day, 2004
|
Low
|
No
|
ADHA
|
Lateral or medial approach
|
5 weekly injections of 25 mg/2.5 ml IA-HA in a phosphate buffered solution or 2.5 ml vehicle or saline
|
DeCaria, 2012
|
Low
|
No
|
NR
|
Anteromedial approach
|
3 weekly injections of IA-HA (2 ml of 20 mg/ml), or saline (1.2 ml of 0.001 mg/ml HA)
|
Diracoglu, 2009
|
High
|
Yes
|
ADHA
|
NR
|
3 weekly injections of IA-HA or saline
|
Dixon, 1988
|
Low
|
No
|
ADHA
|
NR
|
Up to 11 injections of IA-HA (20 mg/2 ml) or placebo (0.2 mg sodium hyaluronate)
|
Henderson, 1994
|
Low
|
No
|
ADHA
|
Medial approach
|
5 weekly injections of IA-HA (20 mg/2 ml) or saline
|
Huang, 2011
|
Low
|
No
|
ADHA
|
NR
|
5 weekly injections of IA-HA (20 mg/2 ml) or saline
|
Huskisson, 1999
|
Low
|
No
|
ADHA
|
NR
|
5 weekly injections of IA-HA (20 mg/2 ml) or saline
|
Jorgensen, 2010
|
Low
|
No
|
ADHA
|
Lateral parapatellar approach
|
5 weekly injections of IA-HA (20 mg/2 ml) or saline
|
Karlsson, 2002
|
High
|
Yes
|
ADHA
|
NR
|
3 weekly injections of IA-HA (Artzal, 2.5 ml or Synvisc, 2.0 ml) or saline
|
Kotevoglu, 2006
|
High
|
Yes
|
ADHA
|
Anterolateral approach
|
3 weekly injections of IA-HA or saline
|
Lohmander, 1996
|
Low
|
No
|
ADHA
|
NR
|
5 weekly injections of IA-HA (25 mg/2.5 ml) or saline
|
Lundsgaard, 2008
|
Low
|
No
|
ADHA
|
Lateral midpatellar portal
|
4 weekly intra-articular injections of IA-HA 2 mL (Hyalgan, 10.3 mg/ml) versus physiological saline 20 ml (distention) versus physiological saline 2 ml
|
Navarro-Sarabia 2011
|
Low
|
No
|
Bio-HA
|
NR
|
4 treatment cycles of 5 weekly injections of IA-HA or saline (2.5 ml)
|
Neustadt, 2005
|
Moderate
|
No
|
Bio-HA
|
Lateral or medial approach
|
4 weekly injections of IA-HA (30 mg/2 ml), or 4 arthrocenteses without injection (control)
|
Petrella, 2006
|
Low
|
no
|
ADHA
|
NR
|
3 weekly injections of IA-HA (20 mg/ml) or saline
|
Petrella, 2008
|
High
|
No
|
ADHA
|
Medial approach
|
3 weekly injections of IA-HA or saline
|
Pham, 2004
|
NR
|
NR
|
NR
|
NR
|
3 weekly injections of IA-HA or saline
|
Puhl, 1993
|
High
|
No
|
ADHA
|
NR
|
5 weekly injections of IA-HA (25 mg/2.5 ml) or dilute IA-HA control(0.25 mg/2.5 ml HA)
|
Scale, 1994
|
High
|
No
|
ADHA
|
NR
|
Two intra-articular injections of IA-HA (2.0 ml) administered 2 weeks apart were compared with three intra-articular injections of IA-HA given 1 week apart vs saline (2.0 ml)
|
Sezgin, 2005
|
Moderate
|
No
|
Bio-HA
|
NR
|
3 weekly injections of IA-HA (15 mg/ml) or saline
|
Strand, 2012
|
High
|
Yes
|
ADHA
|
NR
|
Single 3 ml injection of IA-HA (30 mg/3.0 ml) or saline
|
Tamir, 2001
|
High
|
No
|
Bio-HA
|
NR
|
5 weekly injections of 20 mg IA-HA (10 mg/ml) or saline
|
van der Weegen, 2015
|
Low
|
Yes
|
Bio-HA
|
NR
|
3 weekly injections of IA-HA (15 mg/ml) or saline
|
Wobig, 1998
|
High
|
Yes
|
ADHA
|
NR
|
3 weekly injections of 2.0 ml IA-HA or saline
|